Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6184832 | Gynecologic Oncology | 2015 | 6 Pages |
Abstract
The combination chemotherapy with gemcitabine and vinorelbine achieved the primary end point of our clinical trial in management of platinum resistant recurrent ovarian cancer. However, further sophisticated dosing and scheduling of combination chemotherapy are needed because of a significant proportion of dose reduction.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Sook Hee Hong, Soohyeon Lee, Hoon-Gu Kim, Hyo Jin Lee, Kyung Hae Jung, Sang-Cheol Lee, Na-Ri Lee, Jina Yun, In Sook Woo, Kyong Hwa Park, Kyoung-ha Kim, Ho Young Kim, Sun Young Rha, Jae Ho Byun,